European Clinician and Payer Perspectives on the Dominance of Roche’s MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? - On Demand

Based on our European Physician & Payer Forum report entitled Will Emerging Monoclonal Antibodies Threaten MabThera’s Domination of the Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Markets in Europe? Clinician and Payer Perspectives, Decision Resources is offering an exclusive webinar entitled European Clinician and Payer Perspectives on the Dominance of Roche’s MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? Because this webinar features major report findings, it is ONLY available to purchasers of this report.

Recorded live on Wednesday, September 22, 2010

This webinar, presented by Decision Resources Analyst Andrew Merron, Ph.D. answers the following questions:

• In NHL, what factors both constrain as well as drive the uptake of MabThera? How can emerging MAbs exploit these opportunities?
• In NHL and CLL, which MAbs are currently prescribed, and what are their patient shares by line of treatment for NHL subpopulations such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)?
• What clinical achievements do emerging MAbs need to demonstrate in FL, DLBCL, and CLL in order to oust MabThera from its dominant position? Will emerging MAbs in development meet these requirements? How can emerging MAbs achieve market access without demonstrating superiority over MabThera?
• What features, mechanisms of action and targets of MAbs are considered most promising by surveyed hematologist-oncologists? Which emerging MAbs fulfill these criteria?
• In CLL, what will be the impact of the approval of Arzerra on current clinical practice? How will Arzerra be positioned in the clinical setting and what patient share will Arzerra achieve in CLL and off-label in NHL? How will Arzerra launch impact MabThera in NHL and CLL? What is the sales potential for Arzerra by country?
• Which emerging MAb is considered to be the most promising agent, and which agent is most likely to be prescribed ahead of MabThera?
• How will the anticipated entry of biosimilar rituximab impact sales of currently available MAbs? What are the safety achievements required in order for hematologist-oncologists to switch between branded and biosimilar MAbs?
• How do interviewed payers view the emergence of biosimilar versions of rituximab? What is the outlook for novel emerging MAbs in terms of pricing and reimbursement?

Contact us to learn how you can purchase this Physician & Payer Forum report and access a recorded playback of this event.

Click here to view the invite.